Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003701 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Bladder Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
NCT00003701 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 490 participants.
The verdict
NCT00003701, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether four-drug combination chemotherapy is more effective than two-drug combination chemotherapy in treating bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have bladder cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG paclitaxel
- DRUG methotrexate
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 1999-04-02 |
| Est. Completion | 2007-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003701
The ClinicalTrials.gov registry entry for NCT00003701 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003701 about?
NCT00003701 is a clinical study titled "Combination Chemotherapy in Treating Patients With Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether four-drug combination chemotherapy is more effective than two-drug combination chemotherapy in t...
What is the current status of trial NCT00003701?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 1999-04-02. Estimated completion is 2007-06-15.
What interventions are being tested in trial NCT00003701?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), paclitaxel (DRUG), methotrexate (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003701?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.